The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance

BACKGROUND: Nivolumab and ipilimumab combination therapy is approved in Japan for unresectable or metastatic renal cell carcinoma. Because the clinical trials supporting the approval of nivolumab and ipilimumab combination therapy included relatively few Japanese patients, post-marketing surveillanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Hirotsugu, Shinohara, Nobuo, Tomita, Yoshihiko, Nonomura, Norio, Yamada, Takako, Yoshida, Ai, Komoto, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390800/
https://www.ncbi.nlm.nih.gov/pubmed/37151051
http://dx.doi.org/10.1093/jjco/hyad034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390800/
https://www.ncbi.nlm.nih.gov/pubmed/37151051
http://dx.doi.org/10.1093/jjco/hyad034

Ejemplares similares